TCI Wealth Advisors’s Ventyx Biosciences VTYX Stock Holding History

TCI Wealth Advisors’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-116	Closed	-$3.89K	–	2203
2023 Q1	$3.89K	Hold	116	–	–	﹤0.01%	1706
2022 Q4	$3.8K	Buy	+116	New	+$3.44K	﹤0.01%	1709
2022 Q1	–	Sell	-84	Closed	-$2K	–	2475
2021 Q4	$2K	Buy	+84	New	+$1.59K	﹤0.01%	2131

Other funds holding VTYX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

TCI Wealth Advisors's VTYX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Ventyx Biosciences (VTYX) in Q2 2023, closing a stake of 116 shares — an estimated $3.89K sold.

TCI Wealth Advisors first reported a position in VTYX in Q4 2021 and held it in 3 quarters. The position peaked at $3.89K in Q1 2023. 150 funds tracked by Wall St. Rank hold VTYX as of Q2 2023.

TCI Wealth Advisors reported no remaining Ventyx Biosciences position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 116 Ventyx Biosciences shares in Q2 2023, an estimated $3.89K.
TCI Wealth Advisors first reported a position in Ventyx Biosciences in Q4 2021 and held it in 3 quarters.
TCI Wealth Advisors's Ventyx Biosciences position peaked at $3.89K in Q1 2023.
150 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.